Edward Zdobylak
Neurology · Elk City, OKNPI 1558384545
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,470 of the $59,046 with a category attached, or 68.5%. 36 manufacturers reported payments, led by Biohaven Pharmaceuticals, Inc. at 37.1% of the total. Reporting peaked in 2021 at $36,559 and has fallen 98.4% since, to $577 in 2025.
Across 481 payments — averaging $122.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$22K
- Lilly USA, LLC$13K
- Teva Pharmaceuticals USA, Inc.$9K
- AbbVie$6K
- Promius Pharma LLC$5K
- Novartis$767
- plus $3K from 30 others
What the payments were for
- Consulting fees$8,07514%
- Speaking & faculty fees$40,47069%
- Travel & lodging$2,4634%
- Food & beverage$7,82613%
- Education$2120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 39 | $21,903 |
| Lilly USA, LLC | 55 | $12,845 |
| Teva Pharmaceuticals USA, Inc. | 74 | $9,006 |
| AbbVie(2 entities) | 39 | $6,180 |
| Promius Pharma LLC | 18 | $4,909 |
| Novartis | 43 | $767 |
| Supernus Pharmaceuticals, Inc. | 68 | $637 |
| UCB, Inc. | 17 | $356 |
| Upsher-smith Laboratories LLC | 23 | $348 |
| Livanova USA, Inc. | 27 | $342 |
| Eisai Inc. | 8 | $208 |
| Amgen(2 entities) | 11 | $199 |
| Biogen | 8 | $142 |
| Neurocrine Biosciences, Inc. | 4 | $135 |
| Genentech USA, Inc. | 1 | $126 |
| Lundbeck LLC | 7 | $115 |
| Neurelis, Inc. | 2 | $115 |
| Axsome Therapeutics, Inc. | 3 | $108 |
| Adamas Pharmaceuticals, Inc. | 6 | $103 |
| Sanofi | 4 | $72 |
| Assertio Therapeutics, Inc. | 3 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $47 |
| EMD Serono, Inc. | 3 | $42 |
| AstraZeneca | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Argenx US, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| SK Life Science, Inc. | 1 | $18 |
| Aprecia Pharmaceuticals, LLC | 1 | $17 |
| Harmony Biosciences LLC | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$21,339
- EMGALITY$5,775
- UBRELVY$5,728
- AJOVY$5,350
- AUSTEDO$2,700
- REYVOW$1,925
- VNS Therapy$137
- OCREVUS$126
- Zilbrysq$117
- MAYZENT$105
How this compares
$59,046 in reported general payments places this provider in the 85th percentile of 152 neurology providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 17 | $122,108 |
| AustedoDeutetrabenazine | 12 | $100,772 |
| Nurtec OdtRimegepant Sulfate | 25 | $43,642 |
| Emgality SyringeGalcanezumab-Gnlm | 28 | $30,777 |
| Emgality PenGalcanezumab-Gnlm | 26 | $18,032 |
| Ajovy SyringeFremanezumab-Vfrm | 23 | $17,002 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $15,456 |
| Zolmitriptan | 13 | $6,359 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 185 | $3,842 |
| Donepezil Hcl | 367 | $2,974 |
| Oxcarbazepine | 73 | $2,964 |
| Dimethyl Fumarate | 12 | $2,809 |
| Memantine Hcl | 185 | $2,700 |
| Sumatriptan Succinate | 16 | $2,503 |
| Levetiracetam | 74 | $1,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $9,006 | $222,87929 claims |
| Upsher-smith Laboratories LLCTopiramate | $348 | $86959 claims |
| Lilly USA, LLCOlanzapine | $12,845 | $19415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 152 neurology providers in Oklahoma.
Other neurology in Elk City
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Jaclyn DuvallTulsa$1.4M
- Gregory ConnorTulsa$444K
- Brett DeesNorman$420K
- Eduardo de SousaMoore$393K
- Tania ReynaTulsa$353K
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Baha Abu-EshehArdmore$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.